MORAGA, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that David C. Yeomans, Ph.D., Chief Scientist and Founder of the Company and the Director of Pain Research at Stanford University School of Medicine, presented at the American Headache Society (AHS) 56th Annual Scientific Meeting held on June 26-29, 2014, in Los Angeles, California. Dr. Yeomans was selected by the AHS to present data on Trigemina's lead product candidate, TI-001, an intranasal oxytocin pain therapy. His presentation occurred on June 28, 2014.
"Our research has shown significant promise in the area of chronic and high frequency episodic migraines, a population that suffers greatly from pain," said Dr. Yeomans. "There is a significant unmet medical need for patients with severe migraine and we're eager to share our data at an important platform such as the AHS annual meeting, which provides researchers and physicians with valuable information on emerging therapies such as TI-001. Our goal is to produce a safe, non-addictive and effective solution to people suffering from chronic pain."
TI-001 is currently being evaluated in a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study for efficacy, tolerability and safety in patients with chronic migraine. Promising preclinical and human pilot study results suggests TI-001 could be a safe, non-narcotic form of therapy for the effective relief of chronic migraine, a debilitating condition with few treatment options.
Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.
For additional information, please visit www.trigemina.com